MUHC Vaccine Study Centre

The MUHC Vaccine Study Centre (VSC) conducts vaccine and epidemiological research. Located in Pierrefonds, Quebec, the VSC has conducted over 200 studies with over 8,000 participants enrolled to date.

Want to make a difference? Call 514-624-7855 or text 514-239-7886.

About the MUHC Vaccine Study Centre
Our Team
Ongoing Clinical Studies
Completed Studies
Contact Information

About the MUHC Vaccine Study Centre

Founded in 1991, the MUHC Vaccine Study Centre (VSC) is affiliated with the McGill University Health Centre (MUHC) and the Research Institute of the MUHC (RI-MUHC). The experienced personnel at the VSC conduct vaccine and epidemiological research in collaboration with participants and sponsors. The VSC staff are physicians, nurses and highly trained research personnel, experienced in clinical research and meticulous in their work. They provide a caring, respectful and bilingual environment for study participants.

Our Team

Brian Ward, MD

Co-director

Jesse Papenburg, MD, M.Sc.

Co-director

Deirdre McCormack, B.Sc.(N) RN

Clinical research manager

Lydia Labrie, PhD

Clinical research supervisor

Michael Libman, MD

McGill University Health Centre

Brian Ward, MD

McGill University Health Centre

Jesse Papenburg, MD, M.Sc.

Montreal Children’s Hospital (MUHC)

Earl Rubin, MD

Montreal Children’s Hospital (MUHC)

Inés Colmegna, MD

McGill University Health Centre

Annick Audet, B.Sc.(N), RN

IMPACT Nurse Monitor liaison

Diane Delli Colli, B.Sc.(N), RN

Nurse monitor

Emily Shallhorn, B.Sc.(N), MPH

Nurse monitor back-up

Ongoing Clinical Studies

A Phase I randomized, observer-blind, placebo-controlled trial of a Haemophilus influenzae serotype A (Hia) glycoconjugate vaccine with alum adjuvant in young adults 18 to 40 years of age.

Sponsor: InventVacc Biologicals Inc.
Phase: 1
Target population: adults 18 to 40 years of age
Status: Long-term follow-up

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease

Sponsor: Merck Sharp & Dohme LLC
Phase: 3
Target population: Children and adolescents 2 to 18 years of age with increased risk for pneumococcal disease.
Status: Long-term follow-up

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 18 to 40 Years of Age

Sponsor: Moderna
Phase: 3
Target population: Women aged 18 to 40 years
Status: Long-term follow-up

COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD)

Sponsor: CIHR
Phase: 2/3
Target population: Adults with a systemic autoimmune rheumatic disease
Status: Closed to recruitment

Reinfection in COVID-19 Estimation of Risk: extension

Sponsor: CIHR
Health Care Workers who have had COVID-19
Status: Closed to recruitment. Long-term follow-up.

Efficacy and Safety of MK-1654 in Infants (MK-1654-004)

Sponsor: Merck
Phase: 2/3
Target population: Infants
Status: Closed to recruitment

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Sponsor: Moderna
Phase: 3
Target population: Healthy children aged 6 months to < 12 years
Status: Closed to recruitment. Long-term follow-up.

Interested in more information about our studies? Please contact us.